Adversity is less terrifying than hope: Idexx Laboratories, Inc. (IDXX)

With 0.82 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.43 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $548.88 whereas the lowest price it dropped to was $523.68. The 52-week range on IDXX shows that it touched its highest point at $583.39 and its lowest point at $372.50 during that stretch. It currently has a 1-year price target of $581.34. Beta for the stock currently stands at 1.35.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IDXX was up-trending over the past week, with a rise of 12.62%, but this was up by 12.04% over a month. Three-month performance dropped to -2.15% while six-month performance rose 26.86%. The stock gained 11.97% in the past year, while it has lost -1.17% so far this year. A look at the trailing 12-month EPS for IDXX yields 10.32 with Next year EPS estimates of 12.62. For the next quarter, that number is 2.89. This implies an EPS growth rate of 10.03% for this year and 13.98% for next year. EPS is expected to grow by 12.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 18.76%.

Float and Shares Shorts:

At present, 83.03 million IDXX shares are outstanding with a float of 81.77 million shares on hand for trading. On 2024-04-30, short shares totaled 1.69 million, which was 203.99998999999997 higher than short shares on 1711584000. In addition to Mr. Jonathan J. Mazelsky as the firm’s President, CEO & Director, Mr. Brian P. McKeon serves as its CFO, Executive VP & Treasurer.

Institutional Ownership:

Through their ownership of 0.92499 of IDXX’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, IDXX reported revenue of $964095000.0 and operating income of $298958000.0. The EBITDA in the recently reported quarter was $333294000.0 and diluted EPS was $2.81.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for IDXX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.